5 Most Undervalued Biotech Stocks to Buy According to Analysts

4. POINT Biopharma Global Inc. (NASDAQ:PNT)

Upside Potential as of August 14: 84.00%

PE Ratio (TTM) as of August 14: 8.46

Number of Hedge Fund Holders: 25

POINT Biopharma Global Inc. (NASDAQ:PNT) is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. Its active clinical trials include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer.

On July 20, Jefferies assumed coverage of POINT Biopharma Global Inc. (NASDAQ:PNT) shares with a price target of $14 and a ‘Buy’ rating. The price target represents a potential upside of 60.00% based on the share price on August 14.

As of Q2 2023, POINT Biopharma Global Inc. (NASDAQ:PNT) shares were held by 25 hedge funds with the total shares held by these hedge funds valued at $255 million.